Among Canadians, patients aged 80 years or older are the least likely to have a history of COVID-19 infection and the most likely to be hospitalized or die following infection, data indicate.
The use of nirmatrelvir–ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit.